Efficient Transduction of Myeloid Cells by an HIV-1-derived Lentiviral Vector That Packages the Vpx Accessory Protein

Overview

Journal Gene Ther

Date 2012 Aug 17

PMID 22895508

Citations 56

Authors

S Bobadilla

N Sunseri

N R Landau

Affiliations

Soon will be listed here.

Abstract

Lentiviral vectors are widely used for the stable expression of genes and small hairpin RNA (shRNA)-mediated knockdown and are currently under development for clinical use in gene therapy. Pseudotyping of the vectors with VSV-G allows them to infect a wide range of cell types. However, myeloid cells, such as dendritic cells and macrophages, are relatively refractory to lentiviral vector transduction as a result of the myeloid-specific restriction factor, SAMHD1. SIVmac/HIV-2 and related viruses relieve the SAMHD1-mediated restriction by encoding Vpx, a virion-packaged accessory protein that induces the degradation of SAMHD1 upon infection. HIV-1 does not encode Vpx and cannot package the protein. We report the development of an HIV-1-based lentiviral vector in which the Vpx packaging motif has been placed in the p6 region of the Gag/Pol expression vector that is used to generate the lentiviral vector virions. The virions package Vpx in high copy number and infect myeloid cells with a two-log increase in titer. Transduction of dendritic cells with an shRNA against transportin-3 resulted in >90% knockdown of the encoding mRNA. The system can be applied to any HIV-based lentiviral vector and is useful for laboratory and clinical applications where the efficient transduction of myeloid cells is required.

Citing Articles

Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?.

Bhatia D, Dolcetti R, Mazzieri R J Exp Clin Cancer Res. 2025; 44(1):98.

PMID: 40089746 DOI: 10.1186/s13046-025-03359-x.

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity.

Kong Y, Li J, Zhao X, Wu Y, Chen L Front Immunol. 2025; 15():1519671.

PMID: 39850899 PMC: 11754230. DOI: 10.3389/fimmu.2024.1519671.

programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models.

Argueta S, Wang Y, Zhao H, Diwanji N, Gorgievski M, Cochran E Front Immunol. 2024; 15:1501365.

PMID: 39735543 PMC: 11671302. DOI: 10.3389/fimmu.2024.1501365.

CAR-armored-cell therapy in solid tumor treatment.

Liu Y, Xiao L, Yang M, Chen X, Liu H, Wang Q J Transl Med. 2024; 22(1):1076.

PMID: 39609705 PMC: 11603843. DOI: 10.1186/s12967-024-05903-3.

Protocol for generating human CAR-engineered macrophages by Vpx-containing lentivirus.

Gao Y, Fang X, Zhang L, Yin X STAR Protoc. 2024; 5(4):103350.

PMID: 39342619 PMC: 11735994. DOI: 10.1016/j.xpro.2024.103350.

References

Honke N, Shaabani N, Cadeddu G, Sorg U, Zhang D, Trilling M . Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol. 2011; 13(1):51-7. DOI: 10.1038/ni.2169. View

Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix J . SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology. 2007; 4:2. PMC: 1779362. DOI: 10.1186/1742-4690-4-2. View

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau L . Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther. 2005; 16(1):17-25. DOI: 10.1089/hum.2005.16.17. View

Cartier N, Hacein-Bey-Abina S, von Kalle C, Bougneres P, Fischer A, Cavazzana-Calvo M . [Gene therapy of x-linked adrenoleukodystrophy using hematopoietic stem cells and a lentiviral vector]. Bull Acad Natl Med. 2010; 194(2):255-64. View

Lois C, Hong E, Pease S, Brown E, Baltimore D . Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002; 295(5556):868-72. DOI: 10.1126/science.1067081. View

Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F . Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010; 467(7313):318-22. PMC: 3355472. DOI: 10.1038/nature09328. View

Goujon C, Arfi V, Pertel T, Luban J, Lienard J, Rigal D . Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J Virol. 2008; 82(24):12335-45. PMC: 2593360. DOI: 10.1128/JVI.01181-08. View

Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix J, Cimarelli A . With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther. 2006; 13(12):991-4. DOI: 10.1038/sj.gt.3302753. View

10.

Follenzi A, Ailles L, Bakovic S, Geuna M, Naldini L . Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet. 2000; 25(2):217-22. DOI: 10.1038/76095. View

11.

Sunseri N, OBrien M, Bhardwaj N, Landau N . Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells. J Virol. 2011; 85(13):6263-74. PMC: 3126535. DOI: 10.1128/JVI.00346-11. View

12.

Herchenroder O, Hahne J, Meyer W, Thiesen H, Schneider J . Repression of the human immunodeficiency virus type 1 promoter by the human KRAB domain results in inhibition of virus production. Biochim Biophys Acta. 1999; 1445(2):216-23. DOI: 10.1016/s0167-4781(99)00046-9. View

13.

Dull T, Zufferey R, Kelly M, Mandel R, Nguyen M, Trono D . A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998; 72(11):8463-71. PMC: 110254. DOI: 10.1128/JVI.72.11.8463-8471.1998. View

14.

Spector D, Wade E, Wright D, Koval V, Clark C, Jaquish D . Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol. 1990; 64(5):2298-308. PMC: 249391. DOI: 10.1128/JVI.64.5.2298-2308.1990. View

15.

Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E . HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012; 118(17):4354-62. PMC: 3330145. DOI: 10.1002/cncr.26734. View

16.

Cartier N, Hacein-Bey-Abina S, Bartholomae C, Veres G, Schmidt M, Kutschera I . Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009; 326(5954):818-23. DOI: 10.1126/science.1171242. View

17.

Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage F . In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996; 272(5259):263-7. DOI: 10.1126/science.272.5259.263. View

18.

Wu X, Conway J, Kim J, Kappes J . Localization of the Vpx packaging signal within the C terminus of the human immunodeficiency virus type 2 Gag precursor protein. J Virol. 1994; 68(10):6161-9. PMC: 237035. DOI: 10.1128/JVI.68.10.6161-6169.1994. View

19.

Laguette N, Benkirane M . How SAMHD1 changes our view of viral restriction. Trends Immunol. 2011; 33(1):26-33. PMC: 3595995. DOI: 10.1016/j.it.2011.11.002. View

20.

Campeau E, Ruhl V, Rodier F, Smith C, Rahmberg B, Fuss J . A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One. 2009; 4(8):e6529. PMC: 2717805. DOI: 10.1371/journal.pone.0006529. View